Skip to Main Content
Home
Search
Study Topics
Glossary
Full Text View
Tabular View
No Study Results Posted
Related Studies
Erlotinib in Treating Patients With Advanced Non-Small Cell Lung Cancer, Ovarian Cancer, or Squamous Cell Carcinoma of the Head and Neck
This study has been completed.
Study NCT00063895 Information provided by National Cancer Institute (NCI)
First Received: July 8, 2003 Last Updated: August 19, 2009
History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Drug/Agent Toxicity by Tissue/Organ
Head and Neck Cancer
Lung Cancer
Ovarian Cancer
Additional conditions recognized in this trial
Carcinoma
Carcinoma, Non-Small-Cell Lung
Carcinoma, Squamous Cell
Head and Neck Neoplasms
Lung Neoplasms
Ovarian Neoplasms
More general conditions related to this trial
Adnexal Diseases
Endocrine Gland Neoplasms
Endocrine System Diseases
Genital Diseases, Female
Genital Neoplasms, Female
Gonadal Disorders
Lung Diseases
Neoplasms
Neoplasms by Histologic Type
Neoplasms by Site
Neoplasms, Glandular and Epithelial
Neoplasms, Squamous Cell
Ovarian Diseases
Respiratory Tract Diseases
Respiratory Tract Neoplasms
Thoracic Neoplasms
Urogenital Neoplasms
Interventions listed in this trial
erlotinib hydrochloride
Additional drug interventions recognized in this trial
Erlotinib
More general drug interventions related to this trial
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Protein Kinase Inhibitors
Sponsors listed in this trial
Sidney Kimmel Comprehensive Cancer Center
National Cancer Institute (NCI)
Back to top of Main Content
